Royalty Pharma (RPRX) Long-Term Investments (2019 - 2026)

Royalty Pharma has disclosed Long-Term Investments across 8 years of filings, most recently posting $265.7 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $265.7 million, down 20.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $265.7 million (down 20.97% YoY), and the FY2025 annual result was $419.0 million, up 124.11% from the prior year.
• Long-Term Investments came in at $265.7 million for Q1 2026 at Royalty Pharma, down from $419.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $437.1 million in Q4 2023 to a low of $101.5 million in Q1 2023.
• The 5-year median for Long-Term Investments is $265.7 million (2026), against an average of $255.7 million.
• Peak annual rise in Long-Term Investments reached 289.06% in 2023, while the deepest fall reached 64.78% in 2023.
• Royalty Pharma's Long-Term Investments stood at $112.3 million in 2022, then surged by 289.06% to $437.1 million in 2023, then slumped by 57.23% to $187.0 million in 2024, then surged by 124.11% to $419.0 million in 2025, then plunged by 36.59% to $265.7 million in 2026.
• The last three Long-Term Investments figures came in at $265.7 million (Q1 2026), $419.0 million (Q4 2025), and $129.4 million (Q3 2025), per Business Quant data.